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provided it is propeObjectives: Semen composition is influenced by HIV-1 infection, yet the impact of
semen components on HIV infection of primary target cells has only been studied in
samples from HIV-uninfected donors.
Design: We compared the effect of seminal plasma (SP) from chronically HIV-infected
(SPþ) versus uninfected donors (SP–) on HIV-1 infection of peripheral blood mono-
nuclear cells (PBMCs) and CD4þ T cells.
Methods: Primary cells were infected with HIV-1 in the presence of SPþ or SP– and
analyzed for infection level, metabolic activity, HIV receptor expression, proliferation
and activation. SPþ and SP– were compared for infection-enhancing peptides, cyto-
kines and prostaglandin E2 levels.
Results: SP– efficiently enhanced HIV-1 R5 infection of CD4þ T cells, whereas SPþ
enhancing activity was significantly reduced. RANTES (CCL5) concentrations were
elevated in SPþ relative to SP–, whereas the concentrations of infectivity-enhancing
peptides [semen-derived enhancer of viral infection (SEVI), SEM1, SEM2] were similar.
CCR5 membrane expression levels were reduced on CD4þ T cells shortly postexposure
to SPþ compared with SP– and correlated to R5-tropic HIV-1 infection levels, and
CCR5 ligands’ concentrations in semen. SPþ and SP– displayed similar enhancing
activity on PBMC infection by X4-tropic HIV-1. Addition/depletion of RANTES
(regulated on activation, normal T-cell expressed and secreted) from SPs modulated
their effect on PBMC infection by R5-tropic HIV-1.
Conclusion: Semen from HIV-infected donors exhibits a significantly reduced enhan-
cing potential on CD4þ T-cell infection by R5-tropic HIV-1when comparedwith semen
from uninfected donors. Our data indicate that elevated seminal concentrations of
RANTES in HIV-infected men can influence the ability of semen to enhance infection.
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Semen is the main vector for HIV transmission [1]. In
addition to being a carrier of HIV, semen has been
reported to influence the efficiency of HIV infection of
target cells through the intrinsic properties of its a-cellular
fraction, the seminal plasma (SP) [2–9]. The effects of SP
from HIV-infected men on infection of primary target
cells have not been investigated; all studies so far have
focused on SP provided by uninfected donors and/or
used nonprimary cells as target cells. Several elements
(such as cytokine and microbial content, infection of
semen-producing organs by HIV/SIVand lower ejaculate
volumes in HIV-infected men) indicate that HIV
infection triggers significant alterations in the compo-
sition of SP [3,10–20].
CD4þ T lymphocytes appear to be the primary target for
HIV infection within the semen-exposed mucosa, where
they are present within stratified squamous epithelia and
in subepithelial tissues [21–24]. Breaches in the mucosal
epithelial layer (due to micro-trauma during intercourse
or ulcers resulting from local infections/inflammation)
are frequent, which can bring HIV target cells into direct
contact with semen [23]. In this context, we sought to
compare: the effect of SP from HIV-infected men (SPþ)
versus SP from uninfected donors (SP–) on HIV-1
infection of primary cells; the composition of SPþ versus
SP– in terms of relative levels of infectivity-enhancing
amyloids, cytokines, and prostaglandins; the impact of
SPþ and SP– on CD4þ T-cell surface receptor
expression, activation state, and proliferation.Methods
Semen collection and seminal plasma
preparation
Samples and exposure data were provided by GER-
METHEQUE biobank BB-0033-00081 (France).
Semen was collected from antiretroviral therapy-naive
HIV-infected men (clinical characteristics in Table S1,
http://links.lww.com/QAD/A875) and uninfected
healthy men of proven fertility who gave consent for
semen donation within the framework of our research
protocol, authorized by the French drug safety agency
AFSSAPS (no B90850-30) and Ministe`re de l’enseigne-
ment supe´rieur et de la recherche (no DC-2010-1155).
Individual semen samples from HIV-infected and
uninfected donors were collected, processed and analyzed
using strictly the same procedures at the center for the
cryopreservation of ‘eggs and semen’ (CECOS), follow-
ing World Health Organization (WHO) recommen-
dations [25], as we described [20]. Donors completed a
research questionnaire on uro-genital infections and
infertility risk factors and underwent clinical examin-
ation, as described [20]. None of the HIV-infected and
uninfected men recruited had either clinical evidence ofurogenital infections or medical history of sexually
transmitted infections (apart from HIV) or urinary
infections within the last 5 years. The analysis of semen
parameters (Table S2, http://links.lww.com/QAD/
A876) showed no significant differences in polymorpho-
nuclear cell concentrations (Mann–Whitney test,
P¼ 0.77), spermatozoa concentrations (P¼ 0.61) or
volume (P¼ 0.11) among semen samples from HIV-
infected versus uninfected men. One HIV-infected donor
had a polymorphonuclear cell count above 1 million cell/
ml (leukocytospermia), which may be associated with
genital infection or poor sperm quality [26]. A slightly
higher pH was observed in semen from HIV-infected
versus uninfected men (median of 8.1 versus 7.9,
P¼ 0.02) (Table S2, http://links.lww.com/QAD/
A876). Ejaculates were liquefied for 30min at 378C
and centrifuged 10min at 1000g at room temperature.
SPs were stored at –808C.
HIV-1 variants and virus stocks
HIV-1 clade B strains using as co-receptor for cell entry
either CCR5 (R5 SF162) or CXCR4 (X4 IIIB) were
obtained from the NIBSC (National Institute for
Biological Standards and Control) Centralised Facility
for AIDS Reagents. Viruses were grown in peripheral
blood mononuclear cells (PBMCs) stimulated by
phytohemagglutinin (PHA, 2mg/ml; Sigma Aldrich,
Saint Louis, Missouri, USA) and human recombinant
interleukin-2 (IL-2, 5 ng/ml; Roche Applied Science,
Basel, Switzerland) to provide viral stocks. The culture
supernatants were ultracentrifuged for 1 h at 100 000g on
a 20% sucrose pillow [27]. The resulting virus stocks were
titrated on PBMCs by using the 50% infectivity end-point
method (TCID50) of Reed and Muench [28] and by
measuring p24 concentrations using ELISA. Virus stocks
were stored in aliquot at –808C.
Cell culture and infection
Human PBMCs were purified by ficoll density centrifu-
gation and cultured in RPMI medium (Sigma) supple-
mented with 100U/ml penicillin, 100mg/ml
streptomycin, 2mmol/l L-glutamine and 10% (v/v) fetal
bovine serum. PBMCs were activated with PHA (2mg/
ml) for 72 h and cultured with IL-2 (5 ng/ml) for 24 h
before and after infection. CD4þ T cells were purified
from PHA-stimulated PBMC by negative selection
(Dynabeads UntouchedHuman CD4; Life Technologies,
Carlsbad, California, USA). Of the resulting cell
population, 97% was CD3þCD4þ T lymphocytes,
which underwent IL-2 (5 ng/ml) stimulation for 24 h
before and after infection. PBMCs or purified CD4þ T
cells stimulated with PHA and IL-2 were seeded at
2105 cells/well in 96 well flat-bottom plates in 100ml of
medium. HIV-1 SF162 or IIIB strains (MOI 0.01,
corresponding to 2 or 5 ng/ml p24, respectively) were
mixed with serial dilutions of SP in 11ml of inoculum to
achieve final SP concentration on the cells of 1, 0.2, 0.04
or 0%. Each condition was tested in triplicate. Inoculums
HIV-infected semen and CD4R T-cell infection Camus et al. 1199were removed by centrifugation (280g, 10min) after 3 h
of exposure (unless specified) and fresh medium added.
After 3 days of culture, supernatants were collected and
frozen for p24 viral protein assay by ELISA (Innotest HIV
Antigen mAb; Innogenetics, Zwijnaarde, Belgium). Cell
viability was systematically assessed in all the infectivity
experiments. The number of viable PBMCs was
evaluated as per the manufacturer’s instructions using
the CellTiter-Glo Luminescent Cell Viability Assay
(Promega, Madison, Wisconsin, USA). PBMC viability
at different time points was also assessed using the amine-
reactive red dye (Live/dead Fixable dead cell stain kit; Life
Technologies). Acquisition was performed with a
FACScalibur flow cytometer (Becton Dickinson) and
CELLQuestPro Software was used for analysis.
Real-time PCR and RT-PCR
HIV-1 DNA and RNA and CCR5 mRNA were
measured in PBMCs as previously described [16,29].
PBMCs infected in the presence of nevirapine
(37.5mmol/l) were used for negative control of DNA
originating from the input virus.
Semen-derived enhancer of viral infection and
semenogelin-derived fragments SEM1 (49–107)
and SEM2 (49–107) ELISAs
Semen-derived enhancer of viral infection (SEVI), SEM1
and SEM2 ELISAs were performed as previously
described [4,7].
Cytokines and prostaglandin E2 measurements
Cytokine concentrations were analyzed using the Bio-
Plex Pro assay (Bio-Plex Pro Human Cytokine Group I
[27-plex] and Group II [21-plex] panels; Bio-Rad,
Hercules, California, USA). Total and active transforming
growth factor beta (TGF-b) levels in SP were determined
using the Quantikine human TGF-b kits (R&D Systems,
Minneapolis, Minnesota, USA). Prostaglandin E2
(PGE2) levels were determined using the Prostaglandin
E2 EIA kits (Cayman Chemical Company, Ann Arbor,
Michigan, USA).
Flow cytometry experiments
Cells were stained using fluorescently conjugated
monoclonal antibodies to CD3-PerCP (clone SP34–
2), CD4-FITC (clone RPA-T4), in combination with
either CCR5-PE (clone 3A9), CXCR4-PE (clone
12G5), or the activation marker CD69-PE (clone
FN50), all from BD Biosciences (Franklin Lakes, New
Jersey, USA). Corresponding fluorescent isotype con-
trols were used at the same concentrations as the
reference antibody. Cells were stained with antibodies
by incubation for 30min at 48C, washed in PBS-1%
FCS and fixed in 1.5% paraformaldehyde. Proliferation
assays were performed using the Click-iT EdU Flow
Cytometry Assay kit (Life Technologies), as per
manufacturer instructions. A gate (PBMC gate) was
defined in the analysis to exclude nonviable cells anddebris. The percentage of live/dead cells in the PBMC
gate and in the CD4þ cell population was analyzed
using the Live/dead Fixable dead cell stain kit, as
described above. Acquisition was performed with a
FACScalibur flow cytometer (Becton Dickinson) and
CELLQuestPro Software was used for analysis. The cell
surface expression levels in the flow cytometry profiles
are expressed as mean fluorescence intensity (MFI)
indices. The percentage of stained cells is also
presented.
RANTES addition and depletion experiments
To test the effect of RANTES (regulated on activation,
normal T-cell expressed and secreted) on p24 release from
HIV-1 R5SF162 infected PBMCs, human recombinant
RANTES was added to diluted (1%) SP from uninfected
donors to reach a final concentration of 5 or 10 pg/ml
(corresponding to 500 and 1000 pg/ml, respectively, in
undiluted SP). Conversely, SPs from infected donors were
depleted of RANTES: after a preclearing of IgGs by
incubation with an excess (1mg/ml) of GammaBind
Sepharose beads (GE Healthcare, Little Chalfont,
Buckinghamshire, UK) for 1 h at 48C with rotation,
the beads were removed by centrifugation for 3min at
1500 rpm, and anti-RANTES mAbs (10mg/ml) were
added for 1 h on ice. A second incubation with
GammaBind Sepharose beads was performed, and
immunocomplexes bound to beads removed by centrifu-
gation. Treated samples were tested by ELISA (R&D
Systems) to confirm RANTES depletion.
Statistical analyses
All data were analyzed with the nonparametric Wil-
coxon–Mann–Whitney test. All tests involving more
than two pairwise comparisons were corrected for
multiple testing using Benjamini and Hochberg (FDR)
correction [30]. Correlations were calculated using the
Spearman test. Statistical analyses were performed using
commercially available software (GraphPadPrism 6,
GraphPad Software, Inc., La Jolla, California, USA).Results
We observed that low concentrations of SP (1%), when
incubated with PBMCs for 3 h, demonstrated a dose-
dependent enhancement of HIV infection (Fig. S1A,
http://links.lww.com/QAD/A879) without influencing
cellular metabolism (Fig. S1B, http://links.lww.com/
QAD/A879). This finding is consistent with previous
reports [4,6,7]. In contrast, SP (1%) incubated with
PBMCs for 24 h produced a lower level of HIV infection,
and reduced cellular viability (Fig. S2, http://links.lww.-
com/QAD/A879). These findings are consistent with
previous reports that SP is cytotoxic to PBMCs after
prolonged exposure (>3 h), even when highly diluted
[4,6,31–33]. The results also support a previous finding
1200 AIDS 2016, Vol 30 No 8that the inhibitory activity of SP on CD4þ T cells’
infection is the result of toxicity [4].
Using the noncytotoxic conditions established above, we
then compared SP collected from 20 chronically infected,
therapy-naive HIV-infected donors (SPþ) and 16
uninfected men (SP–) (see Tables S1, http://links.lww.-
com/QAD/A875 and S2, http://links.lww.com/QAD/
A876 for clinical characteristics and semen analyses),
alongside pooled SP from 50 additional uninfected
donors (pool SP–).
SPþ (n¼ 20) displayed a significantly reduced enhancing
effect on PBMC infection by R5-tropic HIV-1 when
compared with SP– (n¼ 16), as measured by p24 ELISA
on culture supernatants 72 h after a 3-h exposure
(significant reduction in three independent experiments
of 47, 35.5 and 24%, with a median enhancement of
1.7–2.9-fold for 1% SP–, donor range 0.98–6.92-fold
versus median 1.5–1.54-fold for 1% SPþ, donor range
0.4–2.8-fold) (Fig. 1a). No differences in PBMC
metabolic activity were ever observed with SPþ or
SP–, whether after the 3-h semen exposure or at the end
of the 72-h culture, and with or without exogenous virus
(Fig. 1b, and Fig. S3, http://links.lww.com/QAD/
A879). In agreement with the p24 assay, the level of
HIV gag RNA within PBMCs exposed to SP– (n¼ 10)
was significantly higher than that in PBMCs exposed to
SPþ (n¼ 10) or to virus only (Fig. 1c). Quantification of
HIVDNA revealed a higher number of HIVDNA copies
in PBMCs exposed to SP– (n¼ 10) versus SPþ (n¼ 10)
from 24 h after the 3-h exposure duration onward
(Fig. 1d). No correlation was found between semen or
blood viral loads of the donors and the level of PBMC
infection following SPþ exposure measured either by p24
ELISA, vRNA or vDNA levels (Spearman test). Similar
to that which was observed in PBMCs, SPþ (n¼ 17) had
a significantly reduced enhancing effect on purified
CD4þ T-cell infection by R5-tropic HIV-1 when
compared with SP– (n¼ 15) (reduction of 22%, with
median enhancement of 2.2-fold for 1% SP–, donor
range 1.5–3.5-fold versus median enhancement 1.7-fold
for 1% SPþ, donor range 0.26–2.88-fold), in the absence
of cytotoxic effect (Fig. 1e and f). The viability of PBMCs
assessed at different time points (24, 48 and 72 h) using
flow cytometry was also similar between cells exposed
to virus only and cells exposed to virus together with SPþ
or SP– (Fig. S4, http://links.lww.com/QAD/A879).
The infection-enhancing properties of semen have been
attributed to seminal amyloid fibrils (SEVI, SEM1 and
SEM2), which promote the attachment of HIV to target
cells [6,7]. The median level of SEVI was similar between
SPþ and SP– (Fig. 2a), whereas slightly higher levels of
SEM1 and SEM2 fragments were observed in SPþ
compared with SP– (Fig. 2b and c). These results indicate
that the lower level of PBMC infection observed with
SPþ compared with SP– was not associated with lowerconcentrations of these peptides. There were no
correlations between the seminal concentrations of those
enhancing peptides and PBMC or purified CD4þ T-cell
infection levels post exposure to SP– or SPþ.
Using Luminex and ELISA, we next investigated the
concentrations of 46 cytokines and that of the main
immunosuppressive seminal prostaglandin, PGE2
(Table S3, http://links.lww.com/QAD/A877). We
found a significant increase in the median concentrations
of five cytokines in SPþ versus SP–: TNFa (1.3-fold),
IL-1b (1.3-fold), IL-1RA (1.2-fold), IL-15 (1.2-fold)
and RANTES (CCL5) (1.9-fold) (Fig. 2d–h, and
Table S3, http://links.lww.com/QAD/A877). Apart
from IL-1RA, a positive correlation was observed
between the levels of those cytokines and the semen
viral loads (Table S4, http://links.lww.com/QAD/
A878), as previously described for RANTES [34],
IL-1b [15,35] and TNFa [14]. RANTES was the only
cytokine for which a consistent (negative) correlation was
observed between its concentrations in semen and the
relative ability of the semen sample to enhance R5-tropic
HIV-1 infection of PBMCs (Spearman test, r¼ –0.387,
P¼ 0.042) (Fig. 2i). We next compared the effect of SPþ
versus SP– on CD4þ T cells’ HIV receptor expression,
activation status and proliferation.We did not observe any
differential effect of SPþ versus SP– on CD4 or CXCR4
expression: CD4 expression on CD3þ T cells was
similarly decreased at 6 and 24 h postexposure to SP– or
SPþ, when compared with infected cells without SP
(Fig. 3a and b). CXCR4 expression on CD4þ T cells was
unchanged at 6 h, and significantly increased at 24 h after
SP– or SPþ exposure (Fig. 3a and c). A positive
correlation with PGE2 concentrations, known to
upregulate CXCR4 [36,37], was observed (Spearman
test, P< 0.001, r¼ 0.68). In contrast, CCR5 expression
was significantly decreased 6 h postexposure to SPþ
when compared with SP– (Fig. 3a and d). This decrease
was transient, as CCR5 membrane expression was
elevated at 24 h postexposure to both SP– and SPþ
when compared with the virus only control (Fig. 3d). No
significant changes in CCR5mRNA copy numbers were
observed at any time points tested, indicating posttran-
scriptional modulation of CCR5 surface expression by SP
(Fig. S5, http://links.lww.com/QAD/A879). The per-
centage of CCR5þ CD4þ T cells at 6 h positively
correlated with the magnitude of infection of PBMCs
(Spearman test, r¼ 0.711, P¼ 0.0025) (Fig. 3e). A
negative correlation was observed between SP-induced
alterations of CCR5 expression level and the added
concentrations of seminal CCR5 ligands RANTES,
MIP1a (CCL3) and MIP1b (CCL4) (Spearman test,
r¼ –0.556, P¼ 0.039) (Fig. 3f). No correlations were
found when RANTES, MIP1a and MIP1b concen-
trations were taken individually. Exposure of PBMCs to
SPþ or SP– triggered a similar decrease of the expression
of the activationmarker CD69 onCD4þT cells as early as
6 h post exposure (Fig. S6A, http://links.lww.com/
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Fig. 1. Effect of SPR versus SP– on R5-tropic HIV-1 infection of PBMCs and CD4R T cells. PBMCs (a–d) or isolated CD4þ T cells
(e and f) were exposed to the indicated dilutions of SPþ or SP– from individual donors (for each condition, each symbol represents
one donor) for 3 h in presence of HIV-1 R5 SF162 strain and then cultured in fresh culture medium. Pooled SP– from 50 additional
uninfected donors was tested in parallel (pool of SP–). Infectivity was measured in PBMCs after 72 h of culture by measuring p24
content in the supernatants (a), by real-time RT-PCR quantification of HIV-1 gag transcripts (c) and by real-time PCR quantification
of HIV-1 long terminal repeat (LTR) DNA in one million PBMCs after 24 h (d). HIV-1 p24 release was measured by ELISA in CD4þ
T-cell supernatants after 72 h of culture (e). (a and e) Results are expressed as fold change relative to virus only for p24 release. (c)
Results are shown as relative expression of HIV gag RNA standardized to GAPDH mRNA expression and (d) as HIV LTR DNA
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(SPþ 1% w/o virus). (b and f) The viability of PBMCs and CD4þ T cells exposed to HIV-1 R5-tropic SF162 in presence of SP from
uninfected or infected donors was evaluated by measuring cellular metabolic activity (ATP levels). Results shown are the mean of
triplicate wells (except mock). The metabolic activity of mock sample (no virus, no seminal plasma) was measured in triplicate
wells in each plate and used as a reference to correct for variations amongst the plates. The result shown for mock condition is the
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(10) instead of the inoculum. Statistical analysis with nonparametric test: Wilcoxon–Mann–Whitney test. P<0.05; P< 0.01;
P<0.001 compared with virus only.QAD/A879). CD4þ T-cell proliferation was not signifi-
cantly different between SP– and SPþ at 24 h and was
slightly higher in presence of SPþ compared with SP– at
48h (Fig. S6B, http://links.lww.com/QAD/A879). Thehigh concentrations of the antiproliferative and immuno-
suppressive molecules PGE2 and TGFbmeasured in both
SPþ and SP– and previously described in semen [38,39]
may contribute to the decreased proliferation of CD4þ
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To investigate whether decreased CCR5 expression was
involved in the reduced infection of PBMC exposed to
SPþ compared with SP–, we analyzed the impact of
SPþ versus SP– on X4-tropic HIV-1 infection. Our
results show that SP– and SPþ had similar enhancing
effects on PBMCs infection by HIV-1 X4 (Fig. 4a). Cell
viability was not affected by SP exposure (Fig. 4b).
We then spiked two SP– pools (from 50 donors each) as
well as SP– from five separate donors with recombinant
RANTES at concentrations similar to those measured in
SPþ (5 and 10 pg/ml in 1% SP, corresponding to 500 and
1000 pg/ml in undiluted SP). The median SP-enhancing
activity of HIV-1 R5-tropic infection of PBMCsdecreased from 2.6 to 1.4-fold in the presence of
5 pg/ml RANTES, and was lost (1-fold) with 10 pg/ml
RANTES (P¼ 0.047) (Fig. 5a). Interestingly, whereas
the addition of RANTES decreased the SP-enhancing
activity of two pools of SP– and three individual SP–
from different donors, the same concentrations of
RANTES had no inhibitory effect in SP– from two
donors (Fig. 5a).
SPþ depleted from RANTES consistently increased
HIV-1 infection levels by a median of 3.6-fold (range
1.8–5.8) that of untouched SPþ in five separate donors
(Fig. 5b). The IgG preclearing step (Fig. 5b), performed
prior to antibody-specific RANTES depletion, only led
to a minor median enhancement of 1.2-fold that of
untouched SPþ (range 1–1.8), together with a slight
decrease in RANTES concentrations in 4/5 samples.
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Understanding the role of semen in HIV transmission is
crucial to the design of effective prevention strategies.
Because cell-free virus was found to infect cervicovaginal
and rectal target cells within 1–4 h postexposure in
macaques [40,41], the most relevant time frame for
studying SP’s impact on HIV transmission is during the
few hours following the intercourse. In addition, short SP
exposure is necessary to avoid SP-induced cytotoxic
effect on CD4þ T cells in culture. Our results show that
under noncytotoxic conditions mimicking rapid infec-
tion of the recipient’s target cells through contaminated
semen, SP from uninfected men enhanced HIV-1
infection of PBMCs. In agreement with Kim et al. [4],
our results suggest that the reported inhibitory effect of
prolonged exposure (>24 h) to SP from uninfected men
of CD4þ T cells [3,5] was due to cytotoxicity.
When comparing SP from infected versus uninfected
men, we found that the enhancement activity mediated
by SPþ was significantly reduced compared with SP–
when R5-tropic infection of PBMCs and CD4þ T cells
was carried out. In contrast, enhancement activity was
similar between SP– and SPþ when PBMCs were
infected with an HIV-1 X4-tropic virus. The viral-
enhancing activity of semen was previously attributed to
positively charged amyloids including SEVI, SEM1 andSEM2 fibrils which capture virions and promote their
attachment to cells [6,7,42]. Our data set of SPþ displayed
similar or even slightly higher concentrations of these
peptides compared with our SP– samples, suggesting that
the lower level of PBMC infection by R5-tropic HIV-1
following exposure to SPþ cannot be explained by a
decreased level of those enhancing peptides.
The comparison of the seminal cytokine contents
between our cohort of infected and uninfected men
showed five significantly elevated cytokines in SPþ. Of
these the CCR5 ligand RANTES showed the highest
increase (2 versus 1.2–1.3-fold for TNFa, IL-1b, IL-15
and IL-1RA). Considerable heterogeneity in semen
cytokine levels exists between cohorts of uninfected
individuals [3,10,38,43] as well as between cohorts of
HIV-infected men [12–14,34,43,44], which likely
reflects both inter-cohorts differences (e.g. number of
individual tested, geographical origins, detection kits
used, etc.) and the wide range of concentrations found for
most cytokines between individuals, which may be linked
to the semen microbiome, HIV load, or genital infections
[3,10,12–14,38,43]. However, the analysis of published
studies on cytokine content in semen from HIVþ men
revealed that RANTES was also elevated in several other
cohorts [13,34,44]. RANTES inhibits infection by
R5-tropic strains through receptor downregulation and
competitive binding to CCR5 [45]. A negative
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Fig. 5. Effect of SPs added or depleted of RANTES on R5-tropic HIV-1 infection of PBMCs. PBMCs were exposed for 3 h to HIV-1
R5-tropic SF162 strain in the presence or absence of SPs (diluted to 1%) and infectivity of PBMCs measured after 72 h of culture in
fresh medium by p24 ELISA on culture supernatants. (a) Human recombinant RANTES was added to 1% SP from two pools of SP–
(each pool derived from 50 uninfected donors) and from five additional uninfected donors. Results representing the mean of
triplicate wells are expressed in fold change compared with virus only. Statistical analysis with nonparametric test: Wilcoxon
matched-pairs signed-rank test. (b) SPs from five HIV-infected donors (SPþ) were first precleared of IgGs (SPþ IgG precleared)
before being depleted of RANTES (SPþ RANTES depleted), as described in methods. Graphs display for each donor both p24
release (expressed in fold change compared with virus only), and RANTES concentrations in 1% SP, before and after IgG
preclearing and RANTES depletion.correlation was consistently and exclusively found
between seminal RANTES concentrations and the SP
infection-enhancing activity during R5-tropic HIV-1
infection of PBMCs. When examining CD4þ T-cells
HIV receptor expression, activation and proliferation at
different time points, the only difference found between
the effects of SP– versus SPþ was a significantly more
pronounced initial decrease of CCR5 surface expression.
This decreased expression most likely reflected down-
modulation of CCR5 rather than a binding competition
between the CCR5 antibody and CCR5 ligands as the
binding site of the CCR5 antibody used (3A9) is different
from that of RANTES, MIP1a and MIP1b [46]. The
percentage of CD4þ T cells expressing CCR5 positively
correlated the magnitude of PBMCs infection and
negatively correlated with the added concentrations of
the CCR5 ligands RANTES, MIP-1a and MIP-1b in
semen. In addition to this, our finding that SPþ and SP–
similarly enhanced HIV-1 IIIB infection of PBMCs
further points to the decreased CCR5 surface expression
by SPþ as a key factor in the lower level of infection
activity in SPþ when compared with that of SP– when
an R5-tropic virus is used in the inoculum. Theunchanged CCR5 mRNA levels post SP– or SPþ
exposure at all-time points suggests modifications of the
intracellular trafficking of the receptor (e.g. enhanced
internalization) compatible with ligand binding. The
addition of recombinant RANTES to SPs from unin-
fected donors led to a decrease in the enhancing activity of
two different pools of SP– from 50 donors each, and
three out of five SP– from separate donors, demonstrat-
ing that RANTES in SP can indeed trigger an inhibitory
effect. Interestingly, our results also suggest that other
semen’s factors (such as the concentrations of enhancing
factors and other CCR5 ligands) may modulate
RANTES inhibitory effect on HIV infection. RANTES
depletion in SPþ samples increased HIV replication,
leading to the suppression of SPþ mediated inhibitory
activity in three of three donors and to an increase of SPþ
mediated enhancing activity in two of two donors. By
contrast, the IgG preclearing step only had a very modest
effect on SPþ activity and, in four of five samples, led to a
slight decrease in RANTES concentrations. These results
indicate that RANTES concentrations in SPs from
different HIV-infected donors indeed influence SP effect
on HIV infection.
1206 AIDS 2016, Vol 30 No 8Semen from HIVþ individuals may contain soluble HIV
proteins, as well as other pathogens, which could also
directly affect HIV infection of target cells. For instance,
soluble gp120 was shown in vitro to either inhibit or
enhance HIV replication, by competing with virions for
CD4þ and co-receptor binding, or inducing cell
signaling, respectively [47–49]. Importantly however,
the concentrations of soluble gp120 in body fluids are
thought to be insufficient to trigger these effects [50].
Thus, a virus-soluble gp120 paired competitive assay
study showed that the effect of the soluble gp120 on
virion entry efficiency could only be seen with high
amount of protein, probably beyond the range of that
found in body fluids [47]. Moreover, soluble gp120-
mediated cross linking to CD4þ receptor was shown to
down-modulate the membrane expression of CD4þ [51]
whereas in our study, we did not observe any specific
effect of SPþ on CD4þ receptor expression when
compared with SP–. As for other soluble viral proteins,
they would potentially affect not only R5 strains, but also
X4 strains, whereas the reduced enhancing activity of
SPþwas specific for R5 strain. Altogether, these elements
argue against a role of soluble HIV proteins in SPþ effect.
Regarding other pathogens, there were no clinical signs
of active co-infections in any of the semen donors, and
except for one HIVþ donor, leukocyte concentrations in
semen were in the normal range, namely below
1million/ml [25]. However, a large proportion of genital
tract infection in men is asymptomatic and a normal
leukocyte cell count in semen does not exclude the
possibility of an infection [26]. Therefore the presence of
other semen-contaminating pathogens cannot be ruled
out. Among those, CMVand HSV-2 have been shown to
directly stimulate HIV-1 R5 entry and replication in
CD4þ cells, notably through increased CCR5 expression
and cell activation [52,53]. This is opposite to the SPþ
effect evidenced in our study, as SPþ decreased HIV R5
infection and CCR5 expression, and both SPþ and SP–
exposure diminished proliferation of CD4þ T cells and
reduced the expression of the activation marker CD69.
Although several other semen-contaminating pathogens
may enhance or inhibit HIV replication in CD4þ cells,
their effects are not specific for HIV R5 strains [54–58].
Thus it is unlikely that other pathogens in semen directly
contributed to the R5 strain-specific reduced enhancing
effect of SPþ.
Overall, we showed that the effect of SP on HIV-1
infection varies depending on the donor status (HIV
infected or not) and viral tropism (R5 versus X4). Our
results indicate that HIV infection significantly modifies
SP composition, and suggest that a balance of stimulatory
(e.g. enhancing amyloids and HIV replication enhancing
cytokines such as IL-1b, TNFa) and inhibitory
molecules (e.g. cytokines like RANTES that decrease
HIV-1 infection) are at play, to which various viral strains
and target cells will be differently susceptible. Forinstance, SP from infected and uninfected men were
recently reported to enhance R5-tropic HIV-1 infection
of TZM-bl to a similar level [2]. Previous reports have
described various effects of SP from uninfected men
depending on the cells, for example, cell lines or different
primary cell types [4,8,9,59–64]. Importantly, to date, all
the in-vivo studies on the impact of SP on HIV
transmission [65–67] have been performed with semen
from uninfected donors. Our results emphasize the
importance of testing semen from infected donors, as
well as whole SP instead of purified seminal factors, to
account for the balance between inhibitory and
stimulatory factors.
In conclusion, this study is the first to directly compare
the effect of SP from HIV-infected and uninfected men
on HIV-1 infection of primary CD4þ T cells. Although
SP from uninfected men enhanced HIV-1 infection of
PBMCs, consistent with previous reports [4,6,7], SP from
infected individuals showed a significantly reduced
enhancing activity when an R5-tropic HIV-1 was used.
Our results suggest that RANTES in semen is at least in
part responsible for the decreased enhancing activity of SP
from infected men. These results highlight the complex
effects of semen on HIV infection and point to the
importance of total consideration of the experimental
system (including the status of semen donor, the target
cell types, and the duration of exposure to semen) when
assessing semen modulating effects. In-vivo experiments
in animal models using semen from infected individuals
are urgently needed to better understand the role of this
complex fluid on HIV transmission.Acknowledgements
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